{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:49:08Z","timestamp":1788518948155,"version":"build-2803163510"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1038\/nrrheum.2012.53","type":"journal-article","created":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T13:16:13Z","timestamp":1335878173000},"page":"399-411","source":"Crossref","is-referenced-by-count":160,"title":["Topical and systemic medications for the treatment of primary Sj\u00f6gren's syndrome"],"prefix":"10.1038","volume":"8","author":[{"given":"Manuel","family":"Ramos-Casals","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Brito-Zer\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Sis\u00f3-Almirall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G.","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,1]]},"reference":[{"key":"BFnrrheum201253_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox, R. I. Sj\u00f6gren's syndrome. Lancet 366, 321\u2013331 (2005).","journal-title":"Lancet"},{"key":"BFnrrheum201253_CR2","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/archinte.164.12.1275","volume":"164","author":"SS Kassan","year":"2004","unstructured":"Kassan, S. S. & Moutsopoulos, H. M. Clinical manifestations and early diagnosis of Sj\u00f6gren syndrome. Arch. Intern. Med. 164, 1275\u20131284 (2004).","journal-title":"Arch. Intern. Med."},{"key":"BFnrrheum201253_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1001\/jama.2010.1014","volume":"304","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals, M., Tzioufas, A. G., Stone, J. H., Sis\u00f3, A. & Bosch, X. Treatment of primary Sj\u00f6gren syndrome: a systematic review. JAMA 304, 452\u2013460 (2010).","journal-title":"JAMA"},{"key":"BFnrrheum201253_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00784-007-0159-3","volume":"12","author":"E Alp\u00f6z","year":"2008","unstructured":"Alp\u00f6z, E. et al. The efficacy of Xialine in patients with Sj\u00f6gren's syndrome: a single-blind, cross-over study. Clin. Oral Investig. 12, 165\u2013172 (2008).","journal-title":"Clin. Oral Investig."},{"key":"BFnrrheum201253_CR5","first-page":"392","volume":"35","author":"MB Alves","year":"2004","unstructured":"Alves, M. B., Motta, A. C., Messina, W. C. & Migliari, D. A. Saliva substitute in xerostomic patients with primary Sj\u00f6gren's syndrome: a single-blind trial. Quintessence Int. 35, 392\u2013396 (2004).","journal-title":"Quintessence Int."},{"key":"BFnrrheum201253_CR6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1600-0714.1992.tb01369.x","volume":"21","author":"A Aagaard","year":"1992","unstructured":"Aagaard, A., Godiksen, S., Teglers, P. T., Schi\u00f8dt, M. & Glenert, U. Comparison between new saliva stimulants in patients with dry mouth: a placebo-controlled double-blind crossover study. J. Oral Pathol. Med. 21, 376\u2013380 (1992).","journal-title":"J. Oral Pathol. Med."},{"key":"BFnrrheum201253_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1741-2358.2001.00087.x","volume":"18","author":"G Johansson","year":"2001","unstructured":"Johansson G. et al. Effects of mouthrinses with linseed extract Salinum without\/with chlorhexidine on oral conditions in patients with Sj\u00f6gren's syndrome. A double-blind crossover investigation. Gerodontology 18, 87\u201394 (2001).","journal-title":"Gerodontology"},{"key":"BFnrrheum201253_CR8","first-page":"28","volume":"29","author":"NL Rhodus","year":"2000","unstructured":"Rhodus, N. L. & Bereuter, J. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sj\u00f6gren's syndrome. J. Otolaryngol. 29, 28\u201334 (2000).","journal-title":"J. Otolaryngol."},{"key":"BFnrrheum201253_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/art.1780390108","volume":"39","author":"WA van der Reijden","year":"1996","unstructured":"van der Reijden, W. A., van der Kwaak, H., Vissink, A., Veerman, E. C. & Amerongen, A. V. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sj\u00f6gren's syndrome. Arthritis Rheum. 39, 57\u201363 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0300-9785(86)80027-8","volume":"15","author":"LL Visch","year":"1986","unstructured":"Visch, L. L., Gravenmade, E. J., Schaub, R. M., Van Putten, W. L. & Vissink, A. A double-blind crossover trial of CMC- and mucin-containing saliva substitutes. Int. J. Oral Maxillofac. Surg. 15, 395\u2013400 (1986).","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"BFnrrheum201253_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/bjo.86.8.879","volume":"86","author":"P Aragona","year":"2002","unstructured":"Aragona, P., Di Stefano, G., Ferreri, F., Spinella, R. & Stilo, A. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sj\u00f6gren's syndrome patients. Br. J. Ophthalmol. 86, 879\u2013884 (2002).","journal-title":"Br. J. Ophthalmol."},{"key":"BFnrrheum201253_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/bjo.86.2.181","volume":"86","author":"P Aragona","year":"2002","unstructured":"Aragona, P., Papa, V., Micali, A., Santocono, M. & Milazzo, G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br. J. Ophthalmol. 86, 181\u2013184 (2002).","journal-title":"Br. J. Ophthalmol."},{"key":"BFnrrheum201253_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00417-004-1040-6","volume":"243","author":"F Brignole","year":"2005","unstructured":"Brignole, F., Pisella, P. J., Dupas, B., Baeyens, V. & Baudouin, C. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch. Clin. Exp. Ophthalmol. 243, 531\u2013538 (2005).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"BFnrrheum201253_CR14","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/bjo.83.10.1121","volume":"83","author":"PI Condon","year":"1999","unstructured":"Condon, P. I. et al. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w\/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br. J. Ophthalmol. 83, 1121\u20131124 (1999).","journal-title":"Br. J. Ophthalmol."},{"key":"BFnrrheum201253_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/sj.eye.6700169","volume":"16","author":"CC McDonald","year":"2002","unstructured":"McDonald, C. C., Kaye, S. B., Figueiredo, F. C., Macintosh, G. & Lockett, C. A randomised, crossover, multicentre study to compare the performance of 0.1% (w\/v) sodium hyaluronate with 1.4% (w\/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond.) 16, 601\u2013607 (2002).","journal-title":"Eye (Lond.)"},{"key":"BFnrrheum201253_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/00003226-199603000-00003","volume":"15","author":"I Toda","year":"1996","unstructured":"Toda, I., Shinozaki, N. & Tsubota, K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sj\u00f6gren's syndrome. Cornea 15, 120\u2013128 (1996).","journal-title":"Cornea"},{"key":"BFnrrheum201253_CR17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/sj.eye.6701537","volume":"19","author":"P Aragona","year":"2005","unstructured":"Aragona, P., Stilo, A., Ferreri, F. & Mobrici, M. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sj\u00f6gren's syndrome patients. Eye (Lond.) 19, 535\u2013539 (2005).","journal-title":"Eye (Lond.)"},{"key":"BFnrrheum201253_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00003226-200003000-00005","volume":"19","author":"R Avisar","year":"2000","unstructured":"Avisar, R., Robinson, A., Appel, I., Yassur, Y. & Weinberger, D. Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis. Cornea 19, 145\u2013147 (2000).","journal-title":"Cornea"},{"key":"BFnrrheum201253_CR19","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0161-6420(00)00538-8","volume":"108","author":"AC Guidera","year":"2001","unstructured":"Guidera, A. C., Luchs, J. I. & Udell, I. J. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 108, 936\u2013944 (2001).","journal-title":"Ophthalmology"},{"key":"BFnrrheum201253_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0002-9394(03)00326-X","volume":"136","author":"AM Avunduk","year":"2003","unstructured":"Avunduk, A. M., Avunduk, M. C., Varnell, E. D. & Kaufman, H. E. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am. J. Ophthalmol. 136, 593\u2013602 (2003).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrrheum201253_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0161-6420(99)90171-9","volume":"106","author":"P Marsh","year":"1999","unstructured":"Marsh, P. & Pflugfelder, S. C. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sj\u00f6gren syndrome. Ophthalmology 106, 811\u2013816 (1999).","journal-title":"Ophthalmology"},{"key":"BFnrrheum201253_CR22","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","volume":"138","author":"SC Pflugfelder","year":"2004","unstructured":"Pflugfelder, S. C. et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am. J. Ophthalmol. 138, 444\u2013457 (2004).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrrheum201253_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1089\/jop.2006.0091","volume":"23","author":"S Hong","year":"2007","unstructured":"Hong, S., Kim, T., Chung, S. H., Kim, E. K. & Seo, K. Y. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sj\u00f6gren's syndrome. J. Ocul. Pharmacol. Ther. 23, 78\u201382 (2007).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"BFnrrheum201253_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/ICO.0b013e3181a16472","volume":"28","author":"MH Dastjerdi","year":"2009","unstructured":"Dastjerdi, M. H., Hamrah, P. & Dana, R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea 28, 1091\u20131096 (2009).","journal-title":"Cornea"},{"key":"BFnrrheum201253_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1755-3768.1994.tb02792.x","volume":"72","author":"K G\u00fcnd\u00fcz","year":"1994","unstructured":"G\u00fcnd\u00fcz, K. & Ozdemir, O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sj\u00f6gren's syndrome. Acta. Ophthalmol. (Copenh.) 72, 438\u2013442 (1994).","journal-title":"Acta. Ophthalmol. (Copenh.)"},{"key":"BFnrrheum201253_CR26","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","volume":"118","author":"KS Kunert","year":"2000","unstructured":"Kunert, K. S., Tisdale, A. S., Stern, M. E., Smith, J. A. & Gipson, I. K. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch. Ophthalmol. 118, 1489\u20131496 (2000).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrrheum201253_CR27","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/ICO.0b013e318074e460","volume":"26","author":"CW Roberts","year":"2007","unstructured":"Roberts, C. W., Carniglia, P. E. & Brazzo, B. G. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea 26, 805\u2013809 (2007).","journal-title":"Cornea"},{"key":"BFnrrheum201253_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.icl.0000170599.57728.29","volume":"32","author":"KN Sall","year":"2006","unstructured":"Sall, K. N., Cohen, S. M., Christensen, M. T. & Stein, J. M. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye. Eye Contact Lens 32, 21\u201326 (2006).","journal-title":"Eye Contact Lens"},{"key":"BFnrrheum201253_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","volume":"107","author":"D Stevenson","year":"2000","unstructured":"Stevenson, D., Tauber, J. & Reis, B. L. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 107, 967\u2013974 (2000).","journal-title":"Ophthalmology"},{"key":"BFnrrheum201253_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/ICO.0b013e3181acf68d","volume":"29","author":"E Toker","year":"2010","unstructured":"Toker, E. & Asfuro\u011flu, E. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy. Cornea 29, 133\u2013140 (2010).","journal-title":"Cornea"},{"key":"BFnrrheum201253_CR31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/archopht.126.8.1046","volume":"126","author":"HD Perry","year":"2008","unstructured":"Perry, H. D. et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch. Ophthalmol. 126, 1046\u20131050 (2008).","journal-title":"Arch. Ophthalmol."},{"key":"BFnrrheum201253_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","volume":"107","author":"K Sall","year":"2000","unstructured":"Sall, K., Stevenson, O. D., Mundorf, T. K. & Reis, B. L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 107, 631\u2013639 (2000).","journal-title":"Ophthalmology"},{"key":"BFnrrheum201253_CR33","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ajo.2008.08.015","volume":"147","author":"EC Kim","year":"2009","unstructured":"Kim, E. C., Choi, J. S. & Joo, C. K. A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome. Am. J. Ophthalmol. 147, 206\u2013213 (2009).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrrheum201253_CR34","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","volume":"112","author":"LD Barber","year":"2005","unstructured":"Barber, L. D., Pflugfelder, S. C., Tauber, J. & Foulks, G. N. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 112, 1790\u20131794 (2005).","journal-title":"Ophthalmology"},{"key":"BFnrrheum201253_CR35","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/01.ico.0000133993.14768.a9","volume":"23","author":"J Tauber","year":"2004","unstructured":"Tauber, J. et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 23, 784\u2013792 (2004).","journal-title":"Cornea"},{"key":"BFnrrheum201253_CR36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/15027732.1986.12461422","volume":"61","author":"M Schi\u00f8dt","year":"1986","unstructured":"Schi\u00f8dt, M., Oxholm, P. & Jacobsen, A. Treatment of xerostomia in patients with primary Sj\u00f6gren's syndrome with sulfarlem. Scand. J. Rheumatol. Suppl. 61, 250\u2013252 (1986).","journal-title":"Scand. J. Rheumatol. Suppl."},{"key":"BFnrrheum201253_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3109\/03009748909099928","volume":"18","author":"NJ Kriegbaum","year":"1989","unstructured":"Kriegbaum, N. J., von Linstow, M., Oxholm, P. & Prause, J. U. A follow-up study of the progress of keratoconjunctivitis sicca and response to treatment in primary Sj\u00f6gren's syndrome. Scand. J. Rheumatol. 18, 193\u2013196 (1989).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum201253_CR38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/15027732.1986.12461423","volume":"61","author":"MT Walters","year":"1986","unstructured":"Walters, M. T., Rubin, C. E., Keightley, S. J., Ward, C. D. & Cawley, M. I. A double-blind, cross-over, study of oral N-acetylcysteine in Sj\u00f6gren's syndrome. Scand. J. Rheumatol. Suppl. 61, 253\u2013258 (1986).","journal-title":"Scand. J. Rheumatol. Suppl."},{"key":"BFnrrheum201253_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1601-0825.2006.01252.x","volume":"13","author":"DJ Aframian","year":"2007","unstructured":"Aframian, D. J. et al. Pilocarpine treatment in a mixed cohort of xerostomic patients. Oral Dis. 13, 88\u201392 (2007).","journal-title":"Oral Dis."},{"key":"BFnrrheum201253_CR40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/bjo.2005.078865","volume":"90","author":"P Aragona","year":"2006","unstructured":"Aragona, P., Di Pietro, R., Spinella, R. & Mobrici, M. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sj\u00f6gren's syndrome. Br. J. Ophthalmol. 90, 166\u2013170 (2006).","journal-title":"Br. J. Ophthalmol."},{"key":"BFnrrheum201253_CR41","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1038\/bdj.2007.80","volume":"202","author":"J Gibson","year":"2007","unstructured":"Gibson, J., Halliday, J. A., Ewert, K. & Robertson, S. A controlled release pilocarpine buccal insert in the treatment of Sj\u00f6gren's syndrome. Br. Dent. J. 202, E17 (2007).","journal-title":"Br. Dent. J."},{"key":"BFnrrheum201253_CR42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/01.rhu.0000135553.08057.21","volume":"10","author":"AS Papas","year":"2004","unstructured":"Papas, A. S. et al. Successful treatment of dry mouth and dry eye symptoms in Sj\u00f6gren's syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J. Clin. Rheumatol. 10, 169\u2013177 (2004).","journal-title":"J. Clin. Rheumatol."},{"key":"BFnrrheum201253_CR43","first-page":"705","volume":"29","author":"NL Rhodus","year":"1998","unstructured":"Rhodus, N. L., Liljemark, W., Bloomquist, C. & Bereuter, J. Candida albicans levels in patients with Sj\u00f6gren's syndrome before and after long-term use of pilocarpine hydrochloride: a pilot study. Quintessence Int. 29, 705\u2013710 (1998).","journal-title":"Quintessence Int."},{"key":"BFnrrheum201253_CR44","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1002\/art.22738","volume":"56","author":"G Peluso","year":"2007","unstructured":"Peluso, G. et al. Proteomic study of salivary peptides and proteins in patients with Sj\u00f6gren's syndrome before and after pilocarpine treatment. Arthritis Rheum. 56, 2216\u20132222 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1601-0825.1997.tb00019.x","volume":"3","author":"NL Rhodus","year":"1997","unstructured":"Rhodus, N. L. Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sj\u00f6gren's syndrome. Oral Dis. 3, 93\u201398 (1997).","journal-title":"Oral Dis."},{"key":"BFnrrheum201253_CR46","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/rheumatology\/41.6.670","volume":"41","author":"J Rosas","year":"2002","unstructured":"Rosas, J. et al. Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sj\u00f6gren's syndrome. Correlation with clinical, immunological and histological features. Rheumatology (Oxford) 41, 670\u2013675 (2002).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201253_CR47","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1136\/ard.2002.003889","volume":"62","author":"N Tsifetaki","year":"2003","unstructured":"Tsifetaki, N. et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sj\u00f6gren's syndrome: a randomised 12 week controlled study. Ann. Rheum. Dis. 62, 1204\u20131207 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR48","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archinte.159.2.174","volume":"159","author":"FB Vivino","year":"1999","unstructured":"Vivino, F. B. et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj\u00f6gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92\u201301 Study Group. Arch. Intern. Med. 159, 174\u2013181 (1999).","journal-title":"Arch. Intern. Med."},{"key":"BFnrrheum201253_CR49","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0929-6646(09)60266-7","volume":"105","author":"CH Wu","year":"2006","unstructured":"Wu, C. H. et al. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sj\u00f6gren's syndrome in Taiwan\u2014a double-blind, placebo-controlled trial. J. Formos. Med. Assoc. 105, 796\u2013803 (2006).","journal-title":"J. Formos. Med. Assoc."},{"key":"BFnrrheum201253_CR50","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/archinte.162.11.1293","volume":"162","author":"RS Fife","year":"2002","unstructured":"Fife, R. S. et al. Cevimeline for the treatment of xerostomia in patients with Sj\u00f6gren syndrome: a randomized trial. Arch. Intern. Med. 162, 1293\u20131300 (2002).","journal-title":"Arch. Intern. Med."},{"key":"BFnrrheum201253_CR51","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3109\/s10165-009-0176-y","volume":"19","author":"K Komai","year":"2009","unstructured":"Komai, K. et al. Sj\u00f6gren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment. Mod. Rheumatol. 19, 416\u2013419 (2009).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum201253_CR52","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10067-007-0723-x","volume":"27","author":"KC Leung","year":"2008","unstructured":"Leung, K. C. et al. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sj\u00f6gren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. Clin. Rheumatol. 27, 429\u2013436 (2008).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201253_CR53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","volume":"138","author":"M Ono","year":"2004","unstructured":"Ono, M. et al. Therapeutic effect of cevimeline on dry eye in patients with Sj\u00f6gren's syndrome: a randomized, double-blind clinical study. Am. J. Ophthalmol. 138, 6\u201317 (2004).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrrheum201253_CR54","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/art.510","volume":"46","author":"D Petrone","year":"2002","unstructured":"Petrone, D. et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sj\u00f6gren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 46, 748\u2013754 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR55","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000084031","volume":"74","author":"K Suzuki","year":"2005","unstructured":"Suzuki, K. et al. Effect of cevimeline on salivary components in patients with Sj\u00f6gren syndrome. Pharmacology 74, 100\u2013105 (2005).","journal-title":"Pharmacology"},{"key":"BFnrrheum201253_CR56","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3899\/jrheum.080370","volume":"35","author":"Y Takagi","year":"2008","unstructured":"Takagi, Y., Katayama, I., Tashiro, S. & Nakamura, T. Parotid irrigation and cevimeline gargle for treatment of xerostomia in Sj\u00f6gren's syndrome. J. Rheumatol. 35, 2289\u20132291 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201253_CR57","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1007\/s10067-006-0507-8","volume":"26","author":"H Yamada","year":"2007","unstructured":"Yamada, H. et al. Efficacy prediction of cevimeline in patients with Sj\u00f6gren's syndrome. Clin. Rheumatol. 26, 1320\u20131327 (2007).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201253_CR58","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/ard.57.8.464","volume":"57","author":"M Izumi","year":"1998","unstructured":"Izumi, M. et al. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sj\u00f6gren's syndrome. Ann. Rheum. Dis. 57, 464\u2013469 (1998).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR59","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2169\/internalmedicine.38.938","volume":"38","author":"S Miyawaki","year":"1999","unstructured":"Miyawaki, S., Nishiyama, S. & Matoba, K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sj\u00f6gren's syndrome. Intern. Med. 38, 938\u2013943 (1999).","journal-title":"Intern. Med."},{"key":"BFnrrheum201253_CR60","first-page":"149","volume":"11","author":"PC Fox","year":"1993","unstructured":"Fox, P. C. et al. Prednisone and piroxicam for treatment of primary Sj\u00f6gren's syndrome. Clin. Exp. Rheumatol. 11, 149\u2013156 (1993).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201253_CR61","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/ard.2006.052647","volume":"66","author":"J Pijpe","year":"2007","unstructured":"Pijpe, J. et al. Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann. Rheum. Dis. 66, 107\u2013112 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR62","first-page":"754","volume":"34","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals, M. et al. High prevalence of serum metabolic alterations in primary Sj\u00f6gren's syndrome: influence on clinical and immunological expression. J. Rheumatol. 34, 754\u2013761 (2007).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201253_CR63","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/ard.52.5.360","volume":"52","author":"AA Kruize","year":"1993","unstructured":"Kruize, A. A. et al. Hydroxychloroquine treatment for primary Sj\u00f6gren's syndrome: a two year double blind crossover trial. Ann. Rheum. Dis. 52, 360\u2013364 (1993).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR64","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/ard.58.4.253","volume":"58","author":"M Tishler","year":"1999","unstructured":"Tishler, M., Yaron, I., Shirazi, I. & Yaron, M. Hydroxychloroquine treatment for primary Sj\u00f6gren's syndrome: its effect on salivary and serum inflammatory markers. Ann. Rheum. Dis. 58, 253\u2013256 (1999).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR65","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/rheumatology\/kep104","volume":"48","author":"M Rihl","year":"2009","unstructured":"Rihl, M., Ulbricht, K., Schmidt, R. E. & Witte, T. Treatment of sicca symptoms with hydroxychloroquine in patients with Sj\u00f6gren's syndrome. Rheumatology (Oxford) 48, 796\u2013799 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201253_CR66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/0002-9343(88)90365-8","volume":"85","author":"RI Fox","year":"1988","unstructured":"Fox, R. I. et al. Treatment of primary Sj\u00f6gren's syndrome with hydroxychloroquine. Am. J. Med. 85, 62\u201367 (1988).","journal-title":"Am. J. Med."},{"issue":"Suppl. 1","key":"BFnrrheum201253_CR67","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1177\/0961203396005001081","volume":"5","author":"RI Fox","year":"1996","unstructured":"Fox, R. I., Dixon, R., Guarrasi, V. & Krubel, S. Treatment of primary Sj\u00f6gren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5 (Suppl. 1), S31\u2013S36 (1996).","journal-title":"Lupus"},{"key":"BFnrrheum201253_CR68","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.tripleo.2010.02.032","volume":"110","author":"H Cankaya","year":"2010","unstructured":"Cankaya, H. et al. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sj\u00f6gren patients: a prospective sample study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 110, 62\u201367 (2010).","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"BFnrrheum201253_CR69","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s00296-010-1415-4","volume":"31","author":"S Yavuz","year":"2011","unstructured":"Yavuz, S., Asfuro\u011flu, E., Bicakcigil, M. & Toker, E. Hydroxychloroquine improves dry eye symptoms of patients with primary Sj\u00f6gren's syndrome. Rheumatol. Int. 31, 1045\u20131049 (2011).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum201253_CR70","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/15027732.1986.12461421","volume":"61","author":"AA Drosos","year":"1986","unstructured":"Drosos, A. A., Skopouli, F. N., Galanopoulou, V. K., Kitridou, R. C. & Moutsopoulos, H. M. Cyclosporin A therapy in patients with primary Sj\u00f6gren's syndrome: results at one year. Scand. J. Rheumatol Suppl. 61, 246\u2013249 (1986).","journal-title":"Scand. J. Rheumatol Suppl."},{"key":"BFnrrheum201253_CR71","first-page":"555","volume":"14","author":"FN Skopouli","year":"1996","unstructured":"Skopouli, F. N., Jagiello, P., Tsifetaki, N. & Moutsopoulos, H. M. Methotrexate in primary Sj\u00f6gren's syndrome. Clin. Exp. Rheumatol. 14, 555\u2013558 (1996).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201253_CR72","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1136\/ard.2006.060905","volume":"66","author":"JM van Woerkom","year":"2007","unstructured":"van Woerkom, J. M. et al. Safety and efficacy of leflunomide in primary Sj\u00f6gren's syndrome: a phase II pilot study. Ann. Rheum. Dis. 66, 1026\u20131032 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR73","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/ar2322","volume":"9","author":"P Willeke","year":"2007","unstructured":"Willeke, P. et al. Mycophenolate sodium treatment in patients with primary Sj\u00f6gren syndrome: a pilot trial. Arthritis Res. Ther. 9, R115 (2007).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201253_CR74","first-page":"896","volume":"25","author":"EJ Price","year":"1998","unstructured":"Price, E. J., Rigby, S. P., Clancy, U. & Venables, P. J. A double blind placebo controlled trial of azathioprine in the treatment of primary Sj\u00f6gren's syndrome. J. Rheumatol. 25, 896\u2013899 (1998).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201253_CR75","first-page":"402","volume":"60","author":"EJ ter Borg","year":"2002","unstructured":"ter Borg, E. J. et al. Treatment of primary Sj\u00f6gren's syndrome with D-penicillamine: a pilot study. Neth. J. Med. 60, 402\u2013406 (2002).","journal-title":"Neth. J. Med."},{"key":"BFnrrheum201253_CR76","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/art.20416","volume":"51","author":"SR Pillemer","year":"2004","unstructured":"Pillemer, S. R. et al. Prominent adverse effects of thalidomide in primary Sj\u00f6gren's syndrome. Arthritis Rheum. 51, 505\u2013506 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR77","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3109\/s10165-007-0627-2","volume":"17","author":"S Nakayamada","year":"2007","unstructured":"Nakayamada, S. et al. Efficacy and safety of mizoribine for the treatment of Sj\u00f6gren's syndrome: a multicenter open-label clinical trial. Mod. Rheumatol. 17, 464\u2013469 (2007).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum201253_CR78","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/rheumatology\/kep228","volume":"48","author":"S Nakayamada","year":"2009","unstructured":"Nakayamada, S. et al. Usefulness of initial histological features for stratifying Sj\u00f6gren's syndrome responders to mizoribine therapy. Rheumatology (Oxford) 48, 1279\u20131282 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201253_CR79","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3109\/s10165-008-0141-1","volume":"19","author":"S Sugai","year":"2009","unstructured":"Sugai, S. et al. Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sj\u00f6gren's syndrome: a double-blind placebo-controlled multicenter trial. Mod. Rheumatol. 19, 114\u2013124 (2009).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum201253_CR80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1477-5751-6-11","volume":"6","author":"H Seitsalo","year":"2007","unstructured":"Seitsalo, H. et al. Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sj\u00f6gren's syndrome: a randomized, double-blind, placebo controlled cross-over study. J. Negat. Results Biomed. 6, 11 (2007).","journal-title":"J. Negat. Results Biomed."},{"key":"BFnrrheum201253_CR81","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1093\/rheumatology\/38.9.814","volume":"38","author":"SD Steinfeld","year":"1999","unstructured":"Steinfeld, S. D., Demols, P., Van Vooren, J. P., Cogan, E. & Appelboom, T. Zidovudine in primary Sj\u00f6gren's syndrome. Rheumatology (Oxford) 38, 814\u2013817 (1999).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201253_CR82","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20540","volume":"51","author":"SR Pillemer","year":"2004","unstructured":"Pillemer, S. R. et al. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sj\u00f6gren's syndrome. Arthritis Rheum. 51, 601\u2013604 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR83","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/ard.2007.071563","volume":"67","author":"A Hartkamp","year":"2008","unstructured":"Hartkamp, A. et al. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sj\u00f6gren syndrome: a randomised controlled trial. Ann. Rheum. Dis. 67, 91\u201397 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR84","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1210\/jc.2009-0106","volume":"94","author":"H Forsbladd'Elia","year":"2009","unstructured":"Forsbladd'Elia, H., Carlsten, H., Labrie, F., Konttinen, Y. T. & Ohlsson, C. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. J. Clin. Endocrinol. Metab. 94, 2044\u20132051 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrrheum201253_CR85","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1167\/iovs.04-1394","volume":"46","author":"P Aragona","year":"2005","unstructured":"Aragona, P., Bucolo, C., Spinella, R., Giuffrida, S. & Ferreri, G. Systemic omega-6 essential fatty acid treatment and PGE1 tear content in Sj\u00f6gren's syndrome patients. Invest. Ophthalmol. Vis. Sci. 46, 4474\u20134479 (2005).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"BFnrrheum201253_CR86","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/03009740252937577","volume":"31","author":"E Theander","year":"2002","unstructured":"Theander, E., Horrobin, D. F., Jacobsson, L. T. & Manthorpe, R. Gammalinolenic acid treatment of fatigue associated with primary Sj\u00f6gren's syndrome. Scand. J. Rheumatol. 31, 72\u201379 (2002).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum201253_CR87","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/03009748609102073","volume":"15","author":"P Oxholm","year":"1986","unstructured":"Oxholm, P., Manthorpe, R., Prause, J. U. & Horrobin, D. Patients with primary Sj\u00f6gren's syndrome treated for two months with evening primrose oil. Scand. J. Rheumatol. 15, 103\u2013108 (1986).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum201253_CR88","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3109\/s10165-008-0078-4","volume":"18","author":"T Kasama","year":"2008","unstructured":"Kasama, T. et al. Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sj\u00f6gren's syndrome. Mod. Rheumatol. 18, 455\u2013459 (2008).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum201253_CR89","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/art.11199","volume":"49","author":"MJ Cummins","year":"2003","unstructured":"Cummins, M. J., Papas, A., Kammer, G. M. & Fox, P. C. Treatment of primary Sj\u00f6gren's syndrome with low-dose human interferon \u03b1 administered by the oromucosal route: combined phase III results. Arthritis Rheum. 49, 585\u2013593 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR90","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1089\/jir.1998.18.255","volume":"18","author":"S Shiozawa","year":"1998","unstructured":"Shiozawa, S., Tanaka, Y. & Shiozawa, K. Single-blinded controlled trial of low-dose oral IFN-\u03b1 for the treatment of xerostomia in patients with Sj\u00f6gren's syndrome. J. Interferon Cytokine Res. 18, 255\u2013262 (1998).","journal-title":"J. Interferon Cytokine Res."},{"key":"BFnrrheum201253_CR91","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1067\/moe.2003.30","volume":"95","author":"AV Khurshudian","year":"2003","unstructured":"Khurshudian, A. V. A pilot study to test the efficacy of oral administration of interferon-\u03b1 lozenges to patients with Sj\u00f6gren's syndrome. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 95, 38\u201344 (2003).","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"BFnrrheum201253_CR92","first-page":"367","volume":"14","author":"GF Ferraccioli","year":"1996","unstructured":"Ferraccioli, G. F. et al. Interferon \u03b12 (IFN \u03b12) increases lacrimal and salivary function in Sj\u00f6gren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin. Exp. Rheumatol. 14, 367\u2013371 (1996).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201253_CR93","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","volume":"44","author":"SD Steinfeld","year":"2001","unstructured":"Steinfeld, S. D., Demols, P., Salmon, I., Kiss, R. & Appelboom, T. Infliximab in patients with primary Sj\u00f6gren's syndrome: a pilot study. Arthritis Rheum. 44, 2371\u20132375 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR94","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/art.20146","volume":"50","author":"X Mariette","year":"2004","unstructured":"Mariette, X. et al. Inefficacy of infliximab in primary Sj\u00f6gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren's Syndrome (TRIPSS). Arthritis Rheum. 50, 1270\u20131276 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR95","first-page":"96","volume":"31","author":"MM Zandbelt","year":"2004","unstructured":"Zandbelt, M. M. et al. Etanercept in the treatment of patients with primary Sj\u00f6gren's syndrome: a pilot study. J. Rheumatol. 31, 96\u2013101 (2004).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201253_CR96","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1002\/art.20299","volume":"50","author":"V Sankar","year":"2004","unstructured":"Sankar, V. et al. Etanercept in Sj\u00f6gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 50, 2240\u20132245 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR97","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"J Meijer","year":"2010","unstructured":"Meijer, J. et al. Effective rituximab treatment in primary Sj\u00f6gren's syndrome: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 960\u2013968 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR98","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"S Dass","year":"2008","unstructured":"Dass, S. et al. Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67, 1541\u20131544 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR99","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/art.22536","volume":"57","author":"V Devauchelle-Pensec","year":"2007","unstructured":"Devauchelle-Pensec, V. et al. Improvement of Sj\u00f6gren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 57, 310\u2013317 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR100","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe, J. et al. Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: an open-label phase II study. Arthritis Rheum. 52, 2740\u20132750 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR101","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard.2006.057919","volume":"66","author":"R Seror","year":"2007","unstructured":"Seror, R. et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren's syndrome. Ann. Rheum. Dis. 66, 351\u2013357 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR102","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/ard.2004.029694","volume":"64","author":"JE Gottenberg","year":"2005","unstructured":"Gottenberg, J. E. et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64, 913\u2013920 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR103","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/ard.2005.046193","volume":"65","author":"M Voulgarelis","year":"2006","unstructured":"Voulgarelis, M., Giannouli, S., Tzioufas, A. G. & Moutsopoulos, H. M. Long term remission of Sj\u00f6gren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann. Rheum. Dis. 65, 1033\u20131037 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR104","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","volume":"71","author":"A Mekinian","year":"2012","unstructured":"Mekinian, A. et al. Efficacy of rituximab in primary Sj\u00f6gren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann. Rheum. Dis. 71, 84\u201387 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR105","first-page":"468","volume":"28","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals, M. et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin. Exp. Rheumatol. 28, 468\u2013476 (2010).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201253_CR106","doi-asserted-by":"publisher","first-page":"R129","DOI":"10.1186\/ar2018","volume":"8","author":"SD Steinfeld","year":"2006","unstructured":"Steinfeld, S. D. et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sj\u00f6gren's syndrome: an open-label phase I\/II study. Arthritis Res. Ther. 8, R129 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201253_CR107","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1001\/jama.2010.1582","volume":"304","author":"A Vissink","year":"2010","unstructured":"Vissink, A., Kallenberg, C. G. & Bootsma, H. Treatment approaches in primary Sjogren syndrome. JAMA 304, 2015\u20132016 (2010).","journal-title":"JAMA"},{"key":"BFnrrheum201253_CR108","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ajo.2007.03.016","volume":"144","author":"KC Yoon","year":"2007","unstructured":"Yoon, K. C. et al. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am. J. Ophthalmol. 144, 86\u201392 (2007).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrrheum201253_CR109","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/bjo.2003.026211","volume":"88","author":"BA Noble","year":"2004","unstructured":"Noble, B. A. et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br. J. Ophthalmol. 88, 647\u2013652 (2004).","journal-title":"Br. J. Ophthalmol."},{"key":"BFnrrheum201253_CR110","first-page":"351","volume":"23","author":"R Belenguer","year":"2005","unstructured":"Belenguer, R. et al. Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sj\u00f6gren's syndrome. Clin. Exp. Rheumatol. 23, 351\u2013356 (2005).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201253_CR111","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1297-319X(01)00341-4","volume":"69","author":"P Ostuni","year":"2002","unstructured":"Ostuni, P. et al. Fibromyalgia in Italian patients with primary Sj\u00f6gren's syndrome. Joint Bone Spine. 69, 51\u201357 (2002).","journal-title":"Joint Bone Spine."},{"key":"BFnrrheum201253_CR112","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1124\/pr.109.002006","volume":"63","author":"P Engel","year":"2011","unstructured":"Engel, P., G\u00f3mez-Puerta, J. A., Ramos-Casals, M., Lozano, F. & Bosch, X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol. Rev. 63, 127\u2013156 (2011).","journal-title":"Pharmacol. Rev."},{"key":"BFnrrheum201253_CR113","first-page":"565","volume-title":"Sj\u00f6gren's Syndrome. Diagnosis and Therapeutics","author":"CP Mavragani","year":"2012","unstructured":"Mavragani, C. P. & Kassan, S. S. in Sj\u00f6gren's Syndrome. Diagnosis and Therapeutics (eds Ramos-Casals, M., Stone, J. & Moutsopoulos, H. M.) 565\u2013570 (Springer-Verlag, Berlin, 2012)."},{"key":"BFnrrheum201253_CR114","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1157\/13115353","volume":"130","author":"P Brito-Zer\u00f3n","year":"2008","unstructured":"Brito-Zer\u00f3n, P. & Ramos-Casals, M. Prognosis of patients with primary Sj\u00f6gren's syndrome [Spanish]. Med. Clin. (Barc.) 130, 109\u2013115 (2008).","journal-title":"Med. Clin. (Barc.)"},{"key":"BFnrrheum201253_CR115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-0-85729-358-9_5","volume-title":"Autoimmune Diseases. Acute and Complex Situations","author":"M Ramos-Casals","year":"2011","unstructured":"Ramos-Casals, M., Brito-Zer\u00f3n, P., Bov\u00e9, A. & Sis\u00f3, A. in Autoimmune Diseases. Acute and Complex Situations (eds Khamashta, M. A. & Ramos-Casals, M.) 45\u201366 (Springer-Verlag, London, 2011)."},{"key":"BFnrrheum201253_CR116","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.3899\/jrheum.110077","volume":"38","author":"RP Pollard","year":"2011","unstructured":"Pollard, R. P. et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sj\u00f6gren's syndrome: a retrospective clinical study. J. Rheumatol. 38, 2198\u20132208 (2011).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201253_CR117","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1002\/art.24903","volume":"60","author":"J Pijpe","year":"2009","unstructured":"Pijpe, J. et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sj\u00f6gren's syndrome. Arthritis Rheum. 60, 3251\u20133256 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR118","first-page":"311","volume":"1","author":"S Jousse-Joulin","year":"2007","unstructured":"Jousse-Joulin, S. et al. Ultrasound assessment of salivary glands in patients with primary Sj\u00f6gren's syndrome treated with rituximab: quantitative and Doppler waveform analysis. Biologics 1, 311\u2013319 (2007).","journal-title":"Biologics"},{"key":"BFnrrheum201253_CR119","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/ard.2006.060772","volume":"66","author":"F Lavie","year":"2007","unstructured":"Lavie, F. et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 66, 700\u2013703 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR120","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/art.27766","volume":"63","author":"FP Strietzel","year":"2011","unstructured":"Strietzel, F. P. et al. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum. 63, 180\u2013190 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201253_CR121","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/ard.2009.110619","volume":"69","author":"R Seror","year":"2010","unstructured":"Seror, R. et al. EULAR Sj\u00f6gren's syndrome disease activity index: development of a consensus systemic disease activity index in primary Sj\u00f6gren's syndrome. Ann. Rheum. Dis. 69, 1103\u20131109 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR122","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/ard.2010.143743","volume":"70","author":"R Seror","year":"2011","unstructured":"Seror, R. et al. EULAR Sj\u00f6gren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sj\u00f6gren's syndrome. Ann. Rheum. Dis. 70, 968\u2013972 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201253_CR123","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/bmj.323.7308.334","volume":"323","author":"R Harbour","year":"2001","unstructured":"Harbour, R. & Miller, J. A new system for grading recommendations in evidence based guidelines. BMJ 323, 334\u2013336 (2001).","journal-title":"BMJ"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2012.53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2012.53","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2012.53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T23:52:56Z","timestamp":1743033176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2012.53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,1]]},"references-count":123,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["BFnrrheum201253"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2012.53","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,1]]}}}